pr_22022010_small_thumb18.jpg bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of its new, ready-to-use culture medium, CampyFood Broth (CFB) for the detection and enumeration of Campylobacter spp. This innovative broth will provide food processing companies with simple, complete and high quality solutions to help ensure the safety of their food products.
bioMérieux's VIDAS SLM, An Officially Recognized MethodSM for Testing Salmonella in Black Pepper
Solution Fully Validated and Recognized as an Official MethodSM
2009 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2009.
bioMérieux Launches a Simple and Rapid VIDAS® L. monocytogenes Testing Solution to Improve Food Safety
3_vidasslide31_thumb16.jpg VIDAS® LMX, a New VIDAS Next Day test for food and environmental testing.
bioMérieux Acquires Chinese Rapid Test Manufacturer Meikang BioTech
Company to leverage new production site to capture growth in China and expand Point of Care and rapid diagnostics offer for both emerging and developed countries
Sepsis and Septic Shock on the Rise, Affecting Younger Patients
Physicians Attribute Antimicrobial Resistance and the Spread of Multi-Drug Resistant Organisms (MDRO) to Antibiotic Overuse
Philips and bioMérieux Announce Partnership to Develop and Market Next-Generation Handheld Diagnostic Solutions for Point-of-Care
Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals.
bioMérieux Launches VIDAS® Free PSA rt BioMarker for Prostate Cancer
New test provides physicians with additional information which may eliminate invasive biopsies
bioMérieux Recognized for Outstanding Service in Physician Office Distribution Network
bioMérieux, a world leader in the field of in vitro diagnostics, has been named the recipient of the Rising Star Award by National Distribution & Contracting, Inc. (NDC) for its outstanding service and support in the physician office market.
Data from Three Clinical Studies of bioTheranostics' Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
Independent studies validate the utility of THEROS BCI® for risk stratification of early stage breast cancer patients and prediction of response to commonly used aromatase inhibitor